6/5
07:30 am
inkt
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
Low
Report
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
5/22
07:45 am
inkt
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting [Yahoo! Finance]
Medium
Report
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting [Yahoo! Finance]
5/22
07:30 am
inkt
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
Medium
Report
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
5/14
11:45 am
inkt
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Medium
Report
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
5/14
07:42 am
inkt
MiNK Reports First Quarter 2024 Results [Yahoo! Finance]
High
Report
MiNK Reports First Quarter 2024 Results [Yahoo! Finance]
5/14
07:30 am
inkt
MiNK Reports First Quarter 2024 Results
High
Report
MiNK Reports First Quarter 2024 Results
5/13
07:46 am
inkt
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer [Yahoo! Finance]
High
Report
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer [Yahoo! Finance]
5/13
07:30 am
inkt
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
Medium
Report
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
4/30
07:30 am
inkt
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
Low
Report
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
4/11
08:37 am
inkt
This MiNK Therapeutics Insider Increased Their Holding In The Last Year [Yahoo! Finance]
Low
Report
This MiNK Therapeutics Insider Increased Their Holding In The Last Year [Yahoo! Finance]
4/8
12:13 pm
inkt
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR [Yahoo! Finance]
Low
Report
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR [Yahoo! Finance]
4/8
12:00 pm
inkt
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
High
Report
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
3/22
01:32 pm
inkt
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/21
11:43 am
inkt
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its price target lowered by analysts at HC Wainwright from $10.00 to $9.00. They now have a "buy" rating on the stock.
Low
Report
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its price target lowered by analysts at HC Wainwright from $10.00 to $9.00. They now have a "buy" rating on the stock.
3/21
07:17 am
inkt
MiNK Reports Fourth Quarter and Year-End 2023 Results [Yahoo! Finance]
Medium
Report
MiNK Reports Fourth Quarter and Year-End 2023 Results [Yahoo! Finance]
3/21
07:00 am
inkt
MiNK Reports Fourth Quarter and Year-End 2023 Results
Low
Report
MiNK Reports Fourth Quarter and Year-End 2023 Results